ѻý

MedpageToday

Checkpoint Inhibitor Checks in as Treatment for Advanced Gastric Cancers

<ѻý class="mpt-content-deck">– PD-L1-positive advanced gastric cancers respond well to pembrolizumab, both alone and with chemotherapy

This Reading Room is a collaboration between ѻý® and:

Medpage Today

Expert Critique

FROM THE ASCO Reading Room
Aparna Parikh, MD, MS
Aparna Parikh, MD, MS Attending Physician Massachusetts General Hospital
Full Critique

Novel immunotherapy drugs such as checkpoint inhibitors have been paradigm changing in melanoma, non-small cell lung cancer, and urothelial cancers. Now evidence points to improved efficacy in patients with gastroesophageal cancer -- in particular, those patients with biomarkers associated with response to treatment, such as programmed death-ligand 1 (PD-L1).

For patients with advanced gastric or gastroesophageal cancers, chemotherapy and targeted therapies such as trastuzumab and ramucirumab have yielded modest improvements in survival, but no long-term cure. Pembrolizumab, already approved for treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction adenocarcinoma who have received multiple rounds of chemotherapy, is now also approved for patients with recurrent, locally advanced, or metastatic squamous cell carcinoma of the esophagus and tumors expressing PD-L1 that progressed after one or more lines of systemic therapy.

As reported at the 2019 ASCO annual meeting, the of pembrolizumab in advanced gastric and gastroesophageal cancer included patients in three different cohorts: cohort 1 had received two or more prior lines of chemotherapy with pembrolizumab alone; and cohorts 2 and 3 treated patients in the first-line setting.

The primary endpoint of cohort 1 was safety and overall response rate (ORR) in all patients and those with a PD-L1-positive combined positive score (CPS) over 1. After a median follow-up of 6 months, the ORR was 11.6%, which was higher for PD-L1-positive patients (15.5%) than for PD-L1-negative patients (6.4%), reported Zev A. Wainberg, MD, of the David Geffen School of Medicine at UCLA, who presented the results.

"The long-term analysis data presented showed durable responses in PD-L1-positive groups," commented the discussant for the study, Osama E. Rahma, MD, of Dana-Farber Cancer Institute in Boston. "This study showed higher and durable response rates in PD-L1-positive CPS over 1 in gastric and gastroesophageal cancer. The safety profile was consistent with prior reports. I think pembrolizumab remains the standard of care in third-line and beyond in PD-L1-positive CPS score over 1 in gastric and gastroesophageal cancer."

In cohort 2, 25 patients received pembrolizumab plus cisplatin and fluorouracil or capecitabine in combination. After a median follow-up of 14 months, the ORR was 60%, which again was higher in PD-L1-positive patients (73.3%) compared with PD-L1-negative patients (37.5%). In cohort 3, 31 patients who had PD-L1 positive tumors received pembrolizumab alone. After 21 months of follow-up, the ORR was 25.8%.

In all three cohorts, the rates of grade 3-5 treatment-related adverse events were 18%, 80%, and 26%, respectively. This led to discontinuation in 2% and 12% of patients in cohorts 1 and 2, respectively; two patients died in cohort 1, and there were no discontinuations or deaths in cohort 3.

"There is promising activity of pembrolizumab as a single agent in PD-L1-positive CPS over 1 in first-line gastroesophageal cancer, and in combination with chemotherapy," said Rahma, who noted that cohorts 2 and 3 had small sample sizes.

He also discussed the results of the in PD-L1-positive patients with CPS over 1. "This abstract showed that pembrolizumab was not inferior to chemotherapy in terms of overall survival (OS) in the first-line setting and had higher magnitude of OS in CPS over 10. However, pembrolizumab in combination with chemotherapy was not superior to chemotherapy alone in terms of OS in CPS 1 or in CPS 10," said Rahma. "I would consider in my clinic pembrolizumab as first-line for PD-L1-positive gastric cancer, especially if the CPS score is over 10, and in patients who are unfit for chemotherapy."

Pembrolizumab in Combination

Also presented at the poster discussion session was a phase II trial of with trastuzumab, capecitabine, and oxaliplatin in 37 patients with HER2-positive metastatic esophageal and gastric adenocarcinoma. The primary endpoint was 6 months progression-free survival (PFS).

After a median follow-up of 10 months, the ORR was 88.6% and the 6-month PFS rate was 74%. There was no correlation between PD-L1 status and PFS or OS, reported Yelena Y. Janjigian, MD, of Memorial Sloan Kettering Cancer Center in New York City.

In his discussant remarks, Rahma again noted the small sample size, but said the results show "a promising signal."

The preliminary safety and efficacy results of this study led to initiation of the definitive , a global, randomized, double-blind study of pembrolizumab, trastuzumab, and chemotherapy versus placebo, trastuzumab, and chemotherapy. This study is currently open for enrollment.

Rahma said that based on the data presented at the ASCO meeting, pembrolizumab should remain the standard of care in third-line or beyond PD-L1 positive CPS over 1 gastric or gastroesophageal cancer. "I think pembrolizumab could now be considered the new standard of care in second-line PD-L1-positive CPS score over 10 in adenocarcinoma and all squamous cell esophageal cancer. Pembrolizumab could also be considered as a first-line in PD-L1-positive CPS score over 1 gastric cancer based on the KEYNOTE-062."

The ongoing KEYNOTE-811 trial raises the following open questions, he added:

  • Based on the data presented at this meeting, how should we move forward with future design in esophageal cancer with immunotherapy?
  • Do we have to take into account race as a condition?
  • Do we have to look at Asian versus non-Asian populations?
  • Should trials focus more on CPS score over 10 based on the separation of the curve that we saw in KEYNOTE-062?
  • Should we look for another biomarker?
  • Should we look for tumor mutational burden or TILs as another biomarker to help us determine which patients would respond?

Rahma also suggested that researchers should consider if they have picked the right backbone chemotherapy, and should think about different chemotherapies that may have different immune modulation effects. In addition, sequencing therapy instead of concurrent administration should be investigated, he said.

"Do we know that the immunogenic cells occur at the same time that it should happen when we target with anti-PD-1? Or should we sequence these therapies starting with chemotherapy followed by pembrolizumab or vice versa?"

Clinicians need combination strategies of chemotherapy with immune checkpoint inhibitors, or possibly other novel agents, to treat their gastric cancer patients in the clinic, he concluded.

Wainberg reported financial relationships with Aduro Biotech, Array BioPharma, Bristol-Myers Squibb, Five Prime Therapeutics, Genentech, Lilly, Merck, Merck KGaA, Novartis, Sirtex, Pfizer, and Plexxikon.

Rahma reported being employed and having a leadership role with Outcomes4me; and financial relationships with Alaunus Global, Clinical Care Options, Leerink, Merck, MI BioResearch, PRIMA, Alcimed, Celgene, Defined Health, Five Prime Therapeutics, Genentech, GfK, GSK, Pure Tech, Putnam Associates, and Amgen.

Janjigian reported financial relationships with Bristol-Myers Squibb, Lilly, Merck, Merck Serono, Pfizer, Amgen, Bayer, Boehringer Ingelheim, Genentech, and Roche.

ASCO Publications Corner

ASCO Publications Corner